EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A case of hyperlysinemia identified by urine newborn screening

Mehdi Yeganeh, Christiane Auray-Blais, Bruno Maranda, Amanda Sabovic, Robert J DeVita, Michael B Lazarus, Sander M Houten iD

JIMD Reports · 2023-11 · 64 (6) · 440-445

DOI: 10.1002/jmd2.12399 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JIMD Reports, online erschienen am 22.10.2023. Verfasst von Mehdi Yeganeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine, Centre Hospitalier Universitaire de Québec, Centre Mère-Enfant Soleil Un…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperlysinemia is a rare autosomal recessive deficiency of 2‐aminoadipic semialdehyde synthase (AASS) affecting the initial step in lysine degradation. It is thought to be a benign biochemical abnormality, but reports on cases remain scarce. The description of additional cases, in particular, those identified without ascertainment bias, may help counseling of new cases in the future. It may also help to establish the risks associated with pharmacological inhibition of AASS, a potential therapeutic strategy that is under investigation for other inborn errors of lysine degradation. We describe the identification of a hyperlysinemia case identified in the Provincial Neonatal Urine Screening Program in Sherbrooke, Quebec. This case presented with a profile of cystinuria but with a very high increase in urinary lysine. A diagnosis of hyperlysinemia was confirmed through biochemical testing and the identification of biallelic variants in AASS . The p.R146W and p.T371I variants are novel and affect the folding of the lysine‐2‐oxoglutarate domain of AASS. The 11‐month‐old boy is currently doing well without any therapeutic interventions. The identification of this case through newborn urine screening further establishes that hyperlysinemia is a biochemical abnormality with limited clinical consequences and may not require any intervention.

Schlagwörter

Stichwörter der Autor:innen

aminoaciduriaascertainment biaslysinenewborn screeningsampling biassubstrate reduction therapy

Autor:innen und Institutionen

  • Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine, Centre Hospitalier Universitaire de Québec, Centre Mère-Enfant Soleil Université Laval Québec City Québec Canada.
  • Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de recherche-CIUSSS de l'Estrie-CHUS Université de Sherbrooke Sherbrooke Québec Canada.
  • Department of Pharmacological Sciences Icahn School of Medicine at Mount Sinai New York New York USA.
  • Drug Discovery Institute Icahn School of Medicine at Mount Sinai New York New York USA.
  • Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA.

ORCID-Profile: Sander M Houten

Förderung

  • NICHD NIH HHS

Zitieren

APA

Yeganeh, M., Auray-Blais, C., Maranda, B., Sabovic, A., DeVita, R. J., Lazarus, M. B., & Houten, S. M. (2023). A case of hyperlysinemia identified by urine newborn screening. JIMD Reports, 64(6), 440-445. https://doi.org/10.1002/jmd2.12399

Vancouver

Yeganeh M, Auray-Blais C, Maranda B, Sabovic A, DeVita RJ, Lazarus MB, et al. A case of hyperlysinemia identified by urine newborn screening. JIMD Reports. 2023;64(6):440-445. doi:10.1002/jmd2.12399

BibTeX
@article{Yeganeh2023,
  author = {Yeganeh, Mehdi and Auray-Blais, Christiane and Maranda, Bruno and Sabovic, Amanda and DeVita, Robert J and Lazarus, Michael B and Houten, Sander M},
  title = {A case of hyperlysinemia identified by urine newborn screening},
  journal = {JIMD Reports},
  year = {2023},
  volume = {64},
  number = {6},
  pages = {440--445},
  doi = {10.1002/jmd2.12399}
}
Kostenlos starten →